Lv3
260 积分 2023-05-12 加入
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges
15天前
已完结
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
15天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
15天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
15天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
16天前
已完结
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study
16天前
已完结
TROP-2–directed antibody–drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes
16天前
已完结
Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences
16天前
已完结
中国神经病理性疼痛诊断及药物治疗指南（2026版）
22天前
已完结
NSCLC: Five trials to watch
1个月前
已完结
皖公网安备34019202002308
